Analysts Issue Forecasts for TESARO Inc’s Q3 2019 Earnings (TSRO)

TESARO Inc (NASDAQ:TSRO) – Stock analysts at Jefferies Financial Group issued their Q3 2019 earnings per share (EPS) estimates for shares of TESARO in a research report issued to clients and investors on Thursday, November 1st. Jefferies Financial Group analyst E. Yang forecasts that the biopharmaceutical company will post earnings of ($2.17) per share for the quarter. Jefferies Financial Group has a “Hold” rating and a $38.00 price target on the stock.

Several other research analysts also recently commented on the company. Bank of America lifted their price objective on TESARO from $38.00 to $39.00 and gave the stock a “neutral” rating in a report on Friday, November 2nd. Wedbush lifted their price objective on TESARO from $60.00 to $67.00 and gave the stock an “outperform” rating in a report on Friday, November 2nd. Oppenheimer set a $83.00 price objective on TESARO and gave the stock a “buy” rating in a report on Thursday, November 1st. Cowen reiterated a “hold” rating and issued a $38.00 price objective on shares of TESARO in a report on Friday, November 2nd. Finally, Cann reiterated a “buy” rating and issued a $83.00 price objective on shares of TESARO in a report on Friday, November 2nd. Nine analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $78.00.

TSRO opened at $29.40 on Monday. The stock has a market capitalization of $1.66 billion, a PE ratio of -3.21 and a beta of 1.35. The company has a current ratio of 4.11, a quick ratio of 3.64 and a debt-to-equity ratio of 3.74. TESARO has a 12 month low of $25.62 and a 12 month high of $113.75.

TESARO (NASDAQ:TSRO) last issued its quarterly earnings results on Thursday, November 1st. The biopharmaceutical company reported ($2.49) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($2.62) by $0.13. The firm had revenue of $64.40 million during the quarter, compared to analyst estimates of $71.84 million. TESARO had a negative return on equity of 563.59% and a negative net margin of 295.67%. The company’s revenue was down 54.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.47) earnings per share.

A number of large investors have recently made changes to their positions in the stock. Commonwealth Equity Services LLC increased its holdings in TESARO by 13.4% during the 3rd quarter. Commonwealth Equity Services LLC now owns 18,822 shares of the biopharmaceutical company’s stock valued at $734,000 after purchasing an additional 2,218 shares during the period. Gabelli Funds LLC increased its holdings in TESARO by 68.8% during the 3rd quarter. Gabelli Funds LLC now owns 23,300 shares of the biopharmaceutical company’s stock valued at $909,000 after purchasing an additional 9,500 shares during the period. US Bancorp DE increased its holdings in TESARO by 163.5% during the 3rd quarter. US Bancorp DE now owns 3,940 shares of the biopharmaceutical company’s stock valued at $153,000 after purchasing an additional 2,445 shares during the period. Frontier Capital Management Co. LLC increased its holdings in TESARO by 77.9% during the 3rd quarter. Frontier Capital Management Co. LLC now owns 3,139,778 shares of the biopharmaceutical company’s stock valued at $122,483,000 after purchasing an additional 1,375,361 shares during the period. Finally, EULAV Asset Management increased its holdings in TESARO by 8.3% during the 3rd quarter. EULAV Asset Management now owns 520,000 shares of the biopharmaceutical company’s stock valued at $20,285,000 after purchasing an additional 40,000 shares during the period.

TESARO Company Profile

Tesaro, Inc, an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It offers ZEJULA (niraparib), an orally active and potent poly polymerase inhibitor for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI (rolapitant), a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting.

Read More: Stop Order Uses For Individual Investors

Earnings History and Estimates for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply